New Drug to Reduce Aging at Fasano Longevity Conference
Dr. Vaughan is Director of the Potocsnak Longevity Institute at Northwestern University. He and his colleagues have developed a drug to reduce PAI-1 levels, a protein associated with blood clotting that causes a number of aging related disorders, as well as more severe COVID outcomes.
Said Fasano Associates’ Mike Fasano, “Doug’s research offers the prospect of reduced morbidity and mortality in the senior population, and also offers a promising therapy to deal with the effects of long COVID. His will be a fascinating presentation.”
The Fasano Conference is a time efficient, one-day event that covers the most current and relevant topics affecting the longevity markets, and has been favored by the investment and financial community. Register now and save over 15% off the regular $595 registration fee.
